Akebia Holds Development Reins In Anemia While Otsuka Jumps On Vadadustat Sleigh
Co-development deal worth $265m in near-term cash will allow Akebia to tap into Otsuka's established kidney disease infrastructure, while holding the reins on key aspects of commercialization.
You may also be interested in...
HIF-PHI inhibitor failed to show non-inferiority to ESAs in the primary cardiovascular safety endpoint of a Phase III program for the treatment of anemia due to chronic kidney disease.
Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.
Japanese firms unveil pivotal top-line results that pave way for first filing of novel anemia therapy within new class of agents, but competition is high and timings remain unclear.